8-K: Personalis Reports Surging Clinical Growth, Medicare Wins

Personalis, Inc. announced a significant surge in clinical test volume and pivotal Medicare coverage approvals for breast and lung cancer surveillance, alongside robust 2026 revenue guidance.

Summary

• Full year 2025 total revenue decreased to $69.6 million from $84.6 million in 2024.
• Clinical test revenue more than doubled in 2025 to $2.0 million from $0.8 million in 2024.
• Clinical test volume surged nearly 400% in 2025 to 16,233 tests, up from 3,285 in 2024.
• Fourth quarter 2025 total revenue increased to $17.3 million from $16.8 million in Q4 2024.
• Q4 2025 clinical test volume was 6,183 tests, a 41% sequential increase over Q3 2025.
• Secured Medicare coverage for breast cancer recurrence surveillance in Q4 2025 and Stage I to III non-small cell lung cancer (NSCLC) in Q1 2026.
• Ended 2025 with approximately $240 million in cash, cash equivalents, and short-term investments.
• Full year 2026 revenue guidance is $78.0 to $80.0 million, with clinical revenue projected to grow approximately five-fold to $10.0 to $11.0 million.
• Expected 2026 clinical volume is 43,000 to 45,000 tests.
• Full year 2026 gross margin guidance is 15% to 20%.
• Full year 2026 net loss is projected at approximately $105.0 million, with cash usage of approximately $100.0 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, driven by significant clinical volume growth and crucial Medicare coverage wins, which are strong indicators for future market penetration and revenue acceleration, despite a current net loss and lower gross margins reflecting strategic investment.

Positives

• Clinical test volume increased nearly 400% year-over-year in 2025 to 16,233 tests.
• Q4 2025 clinical test volume surged 41% sequentially over Q3 2025 to 6,183 tests.
• Secured Medicare coverage for breast cancer recurrence surveillance in Q4 2025, expected to be a key catalyst for clinical revenue.
• Received Medicare coverage for Stage I to III non-small cell lung cancer (NSCLC) in Q1 2026, also expected to drive clinical revenue and market share.
• Strong cash position of approximately $240 million at year-end 2025, providing capital for commercial expansion.
• Published landmark TRACERx data in Cell, demonstrating the clinical importance of the ultrasensitive MRD approach for NSCLC.
• Published VHIO data in Clinical Cancer Research, reinforcing the clinical validity of the NeXT Personal platform across solid tumors.
• Projected 5x growth in clinical revenue for full year 2026, reaching $10.0 to $11.0 million.
• Anticipated clinical volume of 43,000 to 45,000 tests in 2026.

Negatives

• Total revenue for full year 2025 decreased to $69.6 million from $84.6 million in 2024.
• Net loss for full year 2025 was $81.270 million, compared to $81.284 million in 2024.
• Projected net loss for full year 2026 is approximately $105.0 million.
• Expected cash usage for full year 2026 is approximately $100.0 million.
• Gross margin guidance for 2026 is 15% to 20%, reflecting a strategic decision to accelerate clinical volume adoption ahead of full reimbursement coverage, which implies lower profitability in the short term.
• Revenue from enterprise sales (Natera) and population sequencing (VA MVP) significantly decreased from a combined $32.794 million in 2024 to $17.651 million in 2025.

Risks

• Timing and pace of new orders from customers, including ModernaTX, Inc., Merck Sharp & Dohme LLC, other biopharma customers, and the VA MVP.
• Success of clinical sales teams and Tempus AI, Inc.'s sales and marketing efforts.
• Timing of tissue, blood, and other specimen sample receipts from customers, which can materially impact revenue quarter-over-quarter and year-over-year.
• Ability to demonstrate attributes, advantages, or clinical validity of the NeXT platform, including the NeXT Personal MRD assay remaining unique in its ability to detect traces of cancer in the ultrasensitive range.
• Future clinical data differing from the clinical data previously presented or expected results.
• Rate of adoption and use of the NeXT platform, including maintaining the accelerated adoption rates experienced in 2025.
• Ability to obtain Medicare coverage and reimbursement in additional indications and the timing thereof.
• Impact of competition and macroeconomic factors on the business.
• Partnering and/or collaboration arrangements that have been entered into or may be entered into in the future may not be successful, or may terminate, which could adversely impact the business or affect the ability to develop and commercialize services and products.
• Having a limited number of suppliers.
• Customer concentration.
• May opportunistically raise additional capital through equity offerings, debt financings, collaborations, or licensing arrangements.

Future Outlook

Personalis expects total company revenue for full year 2026 to be in the range of $78.0 to $80.0 million, driven by an anticipated five-fold growth in clinical revenue to $10.0 to $11.0 million and clinical volume of 43,000 to 45,000 tests. The company projects a gross margin of 15% to 20% and a net loss of approximately $105.0 million, with cash usage around $100.0 million, reflecting strategic investments in commercial expansion.

Management Comments

• "Our performance in 2025 was transformative, demonstrated by 400% year-over-year clinical volume growth and pivotal Medicare coverage for breast and lung cancer." Chris Hall, CEO and President.
• "We enter 2026 with a fortified balance sheet of approximately $240 million in cash, which allows us to expand our investments in our 'Win-in-MRD' strategy." Chris Hall, CEO and President.
• "While we are in the early stages of reimbursement, we are driving volume now to secure long-term market leadership." Chris Hall, CEO and President.
• "We expect 2026 to be a year of rapid commercial expansion, with clinical revenue projected to grow approximately five-fold as we operationalize our recent coverage wins." Chris Hall, CEO and President.

Industry Context

StockSavvy.ai notes that Personalis's significant increase in clinical test volume and successful Medicare coverage approvals for MRD testing in breast and lung cancer position it favorably within the rapidly expanding precision oncology and liquid biopsy markets. These approvals are critical for broader adoption and reimbursement, aligning with the industry trend towards earlier and more personalized cancer detection and monitoring. Competitors in the MRD space, such as Natera (mentioned in the filing for enterprise sales) and Guardant Health, are also vying for market share, making Personalis's strategic focus on volume adoption ahead of full reimbursement a key differentiator in establishing long-term leadership.

Comparison to Industry Standards

• The 400% year-over-year clinical volume growth in 2025 and projected 5x clinical revenue growth in 2026 for Personalis significantly outpace typical growth rates for established diagnostic companies, indicating strong market penetration for its NeXT Personal platform.
• Securing Medicare coverage for breast and lung cancer surveillance places Personalis in a competitive position against other liquid biopsy providers like Natera (with its Signatera test) and Guardant Health (with its Reveal test), as reimbursement is a critical hurdle for broad adoption in the U.S. market.
• The gross margin guidance of 15% to 20% for 2026 is relatively low compared to mature diagnostic companies, which often achieve gross margins above 50-60%, reflecting Personalis's strategic investment in volume growth ahead of full reimbursement and the early stage of market development for ultrasensitive MRD testing.
• The substantial cash position of $240 million provides a strong runway for Personalis to execute its "Win-in-MRD" strategy, comparable to the capital reserves seen in other high-growth biotech firms investing heavily in R&D and commercialization.

Related Party Transactions

• Includes related party revenue of $1.9 million for Q4 2025 and $5.4 million for FY 2025.
• Includes related party sales and marketing expenses of $1.9 million for Q4 2025 and $4.6 million for FY 2025.
• Includes related party accounts receivable of $2.5 million as of December 31, 2025 and December 31, 2024.
• Includes related party liabilities of $5.7 million as of December 31, 2025 and $1.7 million as of December 31, 2024.
• Includes related party other expense of $18.3 million in connection with the change in fair value of Tempus Warrants for FY 2024.

Stakeholder Impact

• Shareholders: Potential for increased value due to significant clinical growth, Medicare coverage, and strong future revenue guidance, but also continued net losses and cash usage. The ATM sales program diluted shares but strengthened the cash position.
• Patients: Improved access to advanced personalized cancer testing (MRD and recurrence detection) for breast and lung cancer patients due to Medicare coverage.
• Healthcare Providers: Enhanced tools for active cancer management and guiding care throughout the patient journey.
• Employees: Continued investment in commercial expansion suggests potential for growth and stability.
• Customers (Biopharma): Continued revenue from pharma testing services, indicating ongoing partnerships.

Next Steps

• Operationalize recent Medicare coverage wins for breast and lung cancer surveillance to drive clinical revenue.
• Expand investments in the 'Win-in-MRD' strategy.
• Continue driving clinical volume to secure long-term market leadership.
• File Annual Report on Form 10-K for the year ended December 31, 2025, with the SEC on February 26, 2026.

Key Dates

Recommendation

While Personalis demonstrates strong clinical volume growth, pivotal Medicare coverage wins, and a robust cash position, the company continues to project significant net losses and cash usage for 2026, alongside relatively low gross margins. The long-term potential in the MRD market is clear, but the path to profitability remains distant, warranting a 'hold' recommendation as investors await further evidence of successful reimbursement scaling and margin improvement.

Keywords

Personalis, PSNL, genomics, precision oncology, MRD, minimal residual disease, cancer surveillance, Medicare coverage, clinical tests, revenue guidance, biopharma, diagnostics, NSCLC, breast cancer, TRACERx, NeXT Personal, ctDNA